Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-02-05
2010-11-23
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252190, C514S402000, C514S415000, C540S575000, C544S373000, C546S306000, C546S290000
Reexamination Certificate
active
07838518
ABSTRACT:
The present invention relates to 1-arylsulfonyl-3 substituted indole or indoline derivatives having the general formula (I) (I) wherein the dotted line represents an optional bond; n is 0 or 1; m is 0-5 and Ar, R6-R11 are defined in the description. The invention further relates to pharmaceutical compositions comprising said derivatives, and to the use of these 1-arylsulfonyl-3-substituted indole or indoline derivatives in the treatment of central nervous disorders such as psychosis, schizophrenia, manic depressions, depressions, neurological disorders, cognitive enhancement, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease.
REFERENCES:
patent: 4803199 (1989-02-01), Donatsch et al.
patent: 6187805 (2001-02-01), Pineiro et al.
patent: 6251893 (2001-06-01), Maddaford et al.
patent: 6350748 (2002-02-01), Takeyama et al.
patent: 6613781 (2003-09-01), Zhou et al.
patent: 6767912 (2004-07-01), Zhou et al.
patent: 6916812 (2005-07-01), Poindexter et al.
patent: 2006/0223890 (2006-10-01), Ramakrishna et al.
patent: 0 732 333 (1996-09-01), None
patent: WO 96/03400 (1996-02-01), None
patent: WO 01/32660 (2001-05-01), None
patent: WO02/41889 (2002-05-01), None
Pouihes et al. “First synthesis of marine . . . ” CA 139:338117 (2003).
Paxil Drug information Google search result (2007).
Zhou et al. “4-(2-minoethoxy)-N- . . . ” Bioorg. Med. Chem. Lett. v.15, p. 1393-1396 (2005).
Silverman “The organic chemistry of drug design and drug action” p. viii-ix, 72 (1993).
Kobayashi et al “Preparation of sulfonyl . . . ” CA 132:194391 (2000).
DiMalta et al. “Preparaion of N-phenylsulfonyl . . . ” CA 138:137337 (2003).
Spinks et al. “Preparation of 1-arylsulfonyl . . . ” CA 139:197363 (2003).
Ramakrishna et al. “Preparation of N-arylsulfonyl . . . ” CA 141:38523 (2004).
Bissantz et al. “Indole-3-carbonyl . . . ” CA 146:163038 (2007).
Rubini et al. “Synthesis of isosteric . . . ” Tetrahedron v.42 p. 6039-45 (1986).
Cole et al. “Discovery of N1-(6-chloroimidazo . . . ” J. Med. Chem. v.50(23) p. 5535-5538 (2007).
Cole et al. “Conformationally constrained . . . ” Bioorg. med. chem. lett. v. 15 p. 4780-4785 (2005).
Cole et al. “N-arylsuofonyl . . . ” Bioorg. Med. Chem. Lett v. 15, p. 379-383 (2005).
Derivative definition, biology on line, p. 1 (2009).
Bourson A et al. “Determination of the role of . . . ” J. Pharm. Exp. ther. v.274, p. 173-180 (1995).
Ketch, Daniel; et. al., “A Convenient Synthesis of 3-Acylindoles via Friedel-Crafts Acylation of 1-(Phenylsulfonyl)indole. A New Route to Pyridocarbazole-5,11-quinones and Ellipticine”, The Journal of Organic Chemistry; vol. 50, No. 26, 1985.
Russell, Michael, G.N; et. al., “N-Arylsulfonylindole Derivatives as Serotonin 5-HT6Receptor Ligands”, J. Med. Chem, vol. 44, 2001, pp. 3881-3895.
Bourson et al., “Determination of the Role of the 5-ht6Receptor in the Rat Brain: A Study using Antisense Oligonucleotides,”J. Pharmacol. Exp. Ther. 274 (1995) 173-180.
Caulfield et al., “The First Potent and Selective Inhibitors of the Glycine Transporter Type 2,”J. Med. Chem. 44 (2001) 2679-2682.
Cheng et al., “Relationship Between the Inhibition Constant (K1) And The Concentration Of Inhibitor Which Causes 50 Per Cent Inhibition (I50) Of An Enzymatic Reaction,”Biochem. Pharmacol. 22 (1973) 3099-3108.
Ketcha et al., “A Convenient Synthesis of 3-Acylindoles via Friedel-Crafts Acylation of 1-(Pheny1sulfonyl)indole. A New Route to Pyridocarbazole-5,11-quinones and Ellipticine,”J. Org. Chem. 50 (1985) 5451-5457.
Kohen et al., “Cloning, Characterization, and Chromosomal Localization of a Human 5-HT6Serotonin Receptor,”J. Neurochem. 66 (1996) 47-56.
Monsma et al., “Cloning and Expression of a Novel Serotonin Receptor with High Affinity for Tricyclic Psychotropic Drugs,”Mol. Pharm. 43 (1993) 320-327.
Ruat et al., “A Novel Rat Serotonin (5-HT6) Receptor: Molecular Cloning, Localization and Stimulation of cAMP Accumulation,”Biochem. Res. Comm. 193 (1993) 268-276.
Roth et.al.,“Binding of Typical and Atypical Antipsychotic Agents to 5-Hydroxytryptamine-6 and 5-Hydroxytryptamine-7 Receptors,”J. Pharmacol. Exp. Ther. 268 (1994) 1403-1410.
Russell et al., “N-Arylsulfonylindole Derivatives as Serotonin 5-HT6Receptor Ligands,”J. Med. Chem. 44 (2001) 3881-3895.
Sleight et al., “5-HT6and 5-HT7Serotonin Receptors: Molecular Biology and Pharmacology,”Neurotransmissions11 (1995) 1-5.
Armer Richard E.
Jaap David Robert
Mestres Jordi
Miller David J.
Rankovic Zoran
Chang Celia
Hess Susan L.
N.V. Organon
LandOfFree
1-arylsulfonyl-3-substituted indole and indoline derivatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-arylsulfonyl-3-substituted indole and indoline derivatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-arylsulfonyl-3-substituted indole and indoline derivatives... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201114